- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2020–2030 · program · P01
Biology and structure of pMHC receptors functioning as mechanosensors in the [alpha][beta] T-cell lineage
Matthew J. Lang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2028 · research · R25
Advanced Workshop on Research Skills in Oncology
William F Pirl · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2026 · career development · K00
Perturbation based single cell investigation of tumor micro-environment
Chi Zhang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2030 · research · R50
Single cell investigation of co-evolution in cancer cells and host cell immune microenvironment
Shuqiang Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2026 · program · P01
Targeting CDK4 and CDK6 kinases in breast cancer development
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2026 · program · P01
Tissue and Pathology Core
Deborah Dillon · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P01
NMR Methods to decipher the structural and dynamics aspects of TCR mechanobiology
Gerhard Wagner · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2030 · program · P01
Ligand-Dependent [alpha][beta]TCR Function
Matthew J. Lang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P01
Protein Production
Robert Joseph Mallis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Career Enhancement Program (CEP)
Cesar M Castro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinoma
Ursula Anne Matulonis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Project 2: Combined personal neoantigen-targeting cancer vaccines with immune checkpoint blockade for ovarian cancer
Panagiotis Konstantinopoulos · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Organoid, Mouse Model, and Biomarker
Alan D. D'Andrea · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2030 · program · P01
Pre-TCR Mechanotransduction: From Biology to Structure
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P01
Mechanobiology of [alpha][beta]TCRs
Matthew J. Lang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Biostatistics Core
Steven J Skates · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2030 · program · P01
Computational Analysis of TCR Load Propagation and Dynamics
Wonmuk Hwang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Core A: Administrative Core
Alan D. D'Andrea · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2022 · program · P20
Precision Interception of Aggressive Prostate Cancer in African American Men
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Biostatistics Core
Steven J Skates · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2026 · program · P01
Epigenomics Core
Henry W. Long · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)
Geoffrey I Shapiro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)
Geoffrey I Shapiro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P01
Ligand-dependent preTCR function
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinoma
Ursula Anne Matulonis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2030 · program · P01
Protein Production Core
Robert Joseph Mallis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2030 · program · P01
NMR Core
Haribabu Arthanari · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2026 · program · P01
Epigenetic mechanisms of therapeutic resistance
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Pathology Core
David Kolin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P01
Administrative Core
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2026 · program · P01
Targeting Mechanisms of Endocrine Resistance in Breast Cancer
Myles A Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Career Enhancement Program (CEP)
Cesar M Castro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P01
Molecular Dynamics
Wonmuk Hwang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Core A: Administrative Core
Alan D. D'Andrea · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Organoid, Mouse Model, and Biomarker
Alan D. D'Andrea · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2030 · program · P01
Administrative Core
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Developmental Research Program (DRP)
Ursula Anne Matulonis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Developmental Research Program (DRP)
Ursula Anne Matulonis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Project 2: Combined personal neoantigen-targeting cancer vaccines with immune checkpoint blockade for ovarian cancer
Panagiotis Konstantinopoulos · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2026 · program · P01
Administrative Core - New therapeutic vulnerabilities in breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
